Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

Minoxidil use led to unwanted hair growth, but stopping the treatment was not an option due to positive effects on hairline growth. Reducing the dose and using salicylic acid were considered to manage side effects.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

Oral Minoxidil users discuss whether caffeine affects its effectiveness due to adenosine receptor blockade. Users report no significant impact on hair growth despite caffeine consumption.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

Caffeine may interfere with oral minoxidil because caffeine increases blood pressure while minoxidil lowers it. Users discuss potential interactions and effects on hair loss treatment.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

The conversation discusses the effectiveness of Procapil and Vitamin Shampoo for hair loss. Users also mention treatments like Minoxidil, finasteride, and RU58841.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A user praised Kevin Mann for his hair loss advice, crediting finasteride and minoxidil with tretinoin for saving their hair. Other users shared similar experiences and expressed frustration over Mann's channel being affected by past controversies.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation is about whether vellus hair should be included in hair fall counts, with data showing daily hair loss. The consensus is that shedding, including vellus hair, is normal and within physiological limits.

OP asks if face copper peptides from Sephora can be used on the scalp for hair benefits. User233 suggests AHK-CU is mainly for hair, but GHK-CU can also be used.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

A user shared that after quitting caffeine and restarting oral minoxidil, they experienced significant hair regrowth, suggesting that caffeine might interfere with minoxidil's effectiveness by blocking adenosine receptors. They also mentioned side effects like water retention and dizziness, which subsided after a few weeks, and are not using any DHT blockers.

A user is comparing the effectiveness and ingredients of name-brand hair fibers (Nanogen) versus cheaper generic options found on eBay. They are concerned about the presence of sodium chloride in the generic product and seek opinions on whether there is a significant difference in quality.

The conversation discusses verteporfin as a potential hair loss treatment and questions why more precise methods aren't used to test its effectiveness in regrowing hair. Some users believe verteporfin is promising and should receive more attention, while others are skeptical about the testing methods.